Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;10(10):621-625.
doi: 10.4155/tde-2019-0051. Epub 2019 Oct 30.

Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis

Ilaria Testi  1 , Carlos Pavesio  1
Affiliations
Review

Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis

Ilaria Testi et al. Ther Deliv. 2019 Oct.

Abstract

Uveitis is a major cause of ocular morbidity, potentially leading to significant visual impairment. The recent adoption of alternative drug delivery options has led to the development of new sustained-delivery corticosteroid systems, able to manage successfully chronic noninfectious posterior uveitis. The treatment goal is to target the site of inflammation with low dose of corticosteroids, delivered over an extended period of time, to minimize the cumulative damage resulting from repeated recurrences, reducing both injections frequency and ocular side effects. This article will review the pharmacology and preliminary clinical data of the 0.18 mg fluocinolone acetonide intravitreal implant (YUTIQ™), to show its efficacy and safety in the treatment of noninfectious posterior uveitis.

Keywords: YUTIQ™; fluocinolone acetonide; intravitreal corticosteroid implant; noninfectious uveitis; posterior uveitis; sustained-release drug delivery system.

PubMed Disclaimer

Conflict of interest statement

Financial and competing interests disclosure

This work was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Krishna U, Ajanaku D, Denniston AK, Gkika T. Uveitis: a sight-threatening disease which can impact all systems. Postgrad. Med. J. 93, 766–773 (2017). - PubMed
    1. Wakefield D, Chang JH. Epidemiology of uveitis. Int. Ophthalmol. Clin. 45, 1–13 (2005). - PubMed
    1. Bodaghi B, Cassoux N, Wechsler B. et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) 80, 263–270 (2001). - PubMed
    1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111, 491–500 (2004). - PubMed
    1. Retisert Prescribing Information. http://www.bausch.com/Portals/107/-/m/BL/United%20States/USFiles/Package...

Publication types

MeSH terms